![](https://images.squarespace-cdn.com/content/v1/54c68ac6e4b06d2e36a4b8c9/1585411667181-4DAUOCOD82BM712P2DRA/image-asset.jpeg)
LATEST NEWS IN PROSTATE CANCER
XTANDI® (ENZALUTAMIDE) APPROVED BY U.S. FDA FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).